Avalon GloboCare Corp(ALBT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -8.25 | Insider Own | 7.19% | Shs Outstand | 14.5M | Perf Week | 8.16% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 13.5M | Perf Month | -18.5% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | - | Inst Own | 9.28% | Short Float | 0.89% | Perf Quarter | -43.43% |
| Income | -0.02B | P/S | 3.84 | EPS this Y | - | Inst Trans | 9.12% | Short Ratio | 0.08 | Perf Half Y | -76.32% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -78.94% | Short Interest | 0.12M | Perf YTD | -76.91% |
| Book/sh | -1.81 | P/C | 5.16 | EPS past 3/5Y | 33.45% 25.06% | ROE | -214.52% | 52W High | -94.15% ($4.74) | Perf Year | -88.06% |
| Cash/sh | 0.05 | P/FCF | - | Sales past 3/5Y | - | ROIC | -155.2% | 52W Low | 31.95% ($0.21) | Perf 3Y | -98.73% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 75.73% | Gross Margin | 44.4% | Volatility(W/M) | 21.7% 11.71% | Perf 5Y | -99.8% |
| Dividend TTM | - | EV/Sales | 29.99 | Sales Y/Y TTM | -21.23% | Oper. Margin | -733.08% | ATR (14) | 0.04 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.36 | EPS Q/Q | 67.29% | Profit Margin | -1743.75% | RSI (14) | 43.31 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.38 | Sales Q/Q | -100% | SMA20 | -4.06% ($0.29) | Beta | -0.04 | Target Price | - |
| Payout | - | Debt/Eq | 0.12 | Earnings | - | SMA50 | -14.78% ($0.33) | Rel Volume | 5.96 | Prev Close | $0.29 |
| Employees | 2 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | - | SMA200 | -70.79% ($0.96) | Avg Volume(3M) | 1.56M | Price | $0.28 |
| IPO | 2016/12/6 | Option/Short | No/Yes | Trades | 5806 | Volume | 9,269,003 | Change | -3.18% |
🧬 (Avalon GloboCare) is a US Nasdaq-listed healthcare company that develops precision diagnostic consumer products alongside cellular therapy (CAR-T and CAR-NK) intellectual property. It operates a diversified business structure featuring its proprietary breath analysis device, KetoAir™, and clinical-stage CAR-T candidates (including AVA-001), while recognizing a portion of its revenue through a clinical trial management services (MSO) subsidiary.
Over the past 1 year, on the lower side
94% below its 1-year high.
Traded more than usual. That is 596% of its average volume.
ALBT has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $384. Peers typically go for $117.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +64% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 9.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #41 of 46 in the industry
Based on market cap of $4M.
GYRO#39 Gyrodyne LLC $8M PER - 
FTHM#40 Fathom Holdings Inc $5M PER - ALBT#41 Avalon GloboCare Corp $4M PER - 
GBR#41 New Concept Energy Inc $3M PER - 
AIRE#42 reAlpha Tech Corp $2M PER - 
FAQ
What kind of company is ALBT?
ALBT belongs to the Real Estate sector and operates in the Real Estate Services industry.
What is the market cap of ALBT?
The market cap of ALBT is approximately $4M, ranking 5,731 within its sector.
What is the 52-week high and low for ALBT?
ALBT has recorded a 52-week high of $4.74 and a low of $0.21.
